- Home
- BCML vs DMAC Comparison
BCML vs DMAC Comparison
Compare BCML & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCML
- DMAC
- Stock Information
- Founded
- BCML 2004
- DMAC 2000
- Country
- BCML United States
- DMAC United States
- Employees
- BCML N/A
- DMAC N/A
- Industry
- BCML Major Banks
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- BCML Finance
- DMAC Health Care
- Exchange
- BCML Nasdaq
- DMAC Nasdaq
- Market Cap
- BCML 312.0M
- DMAC 310.1M
- IPO Year
- BCML N/A
- DMAC N/A
- Fundamental
- Price
- BCML $30.48
- DMAC $5.98
- Analyst Decision
- BCML Strong Buy
- DMAC Strong Buy
- Analyst Count
- BCML 1
- DMAC 3
- Target Price
- BCML $32.00
- DMAC $12.33
- AVG Volume (30 Days)
- BCML 21.7K
- DMAC 314.0K
- Earning Date
- BCML 10-16-2025
- DMAC 08-12-2025
- Dividend Yield
- BCML 2.62%
- DMAC N/A
- EPS Growth
- BCML 2.85
- DMAC N/A
- EPS
- BCML 2.18
- DMAC N/A
- Revenue
- BCML $96,577,000.00
- DMAC N/A
- Revenue This Year
- BCML $5.47
- DMAC N/A
- Revenue Next Year
- BCML $8.08
- DMAC N/A
- P/E Ratio
- BCML $14.02
- DMAC N/A
- Revenue Growth
- BCML N/A
- DMAC N/A
- 52 Week Low
- BCML $21.66
- DMAC $3.19
- 52 Week High
- BCML $30.90
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- BCML 69.42
- DMAC 65.09
- Support Level
- BCML $28.31
- DMAC $5.90
- Resistance Level
- BCML $30.65
- DMAC $6.18
- Average True Range (ATR)
- BCML 0.78
- DMAC 0.39
- MACD
- BCML 0.29
- DMAC 0.02
- Stochastic Oscillator
- BCML 88.95
- DMAC 79.10
About BCML BayCom Corp
BayCom Corp is a bank holding company for United Business Bank. It provides a broad range of financial services to businesses and business owners as well as individuals through its full-service branches and loan production office. The company targets its services to small and medium-sized businesses, professional firms, real estate professionals, nonprofit businesses, labor unions, and related nonprofit entities and businesses and individual consumers. Its products and services include deposit products, personal accounts, loans, online banking, cash management, and business savings services.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.